We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 27th:
Cleveland-Cliffs Inc. (CLF - Free Report) : This owner and operator of an iron ore mining company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 41% over the last 60 days.
Align Technology, Inc. (ALGN - Free Report) : This designer and manufacturer of clear aligner therapy systems and intraoral scanners has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings climbing 3.6% over the last 60 days.
BioLife Solutions, Inc. (BLFS - Free Report) : This developer of medical instruments has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings jumping more than 100% over the last 60 days.
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Top Ranked Momentum Stocks to Buy for July 27th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 27th:
Cleveland-Cliffs Inc. (CLF - Free Report) : This owner and operator of an iron ore mining company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 41% over the last 60 days.
Cleveland-Cliffs Inc. Price and Consensus
Cleveland-Cliffs Inc. price-consensus-chart | Cleveland-Cliffs Inc. Quote
Cleveland-Cliffs’ shares gained 28.7% over the last one month more than S&P 500’s gain of 4.5%. The company possesses a Momentum Score of B.
Cleveland-Cliffs Inc. Price
Cleveland-Cliffs Inc. price | Cleveland-Cliffs Inc. Quote
Align Technology, Inc. (ALGN - Free Report) : This designer and manufacturer of clear aligner therapy systems and intraoral scanners has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings climbing 3.6% over the last 60 days.
Align Technology, Inc. Price and Consensus
Align Technology, Inc. price-consensus-chart | Align Technology, Inc. Quote
Align Technology’s shares gained 5.6% over the last one month. The company possesses a Momentum Score of A.
Align Technology, Inc. Price
Align Technology, Inc. price | Align Technology, Inc. Quote
BioLife Solutions, Inc. (BLFS - Free Report) : This developer of medical instruments has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings jumping more than 100% over the last 60 days.
BioLife Solutions, Inc. Price and Consensus
BioLife Solutions, Inc. price-consensus-chart | BioLife Solutions, Inc. Quote
BioLife’s shares gained 80.8% over the last one month. The company possesses a Momentum Score of A.
BioLife Solutions, Inc. Price
BioLife Solutions, Inc. price | BioLife Solutions, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>